From Concept to Clinic: How We Are Building and Testing This System

Dhereputics is currently in the earliest stages of development, where the focus is not on scale or commercialisation, but on understanding whether the underlying concept can be made scientifically robust. At this stage, the most important question is simple: can a biomaterial system be engineered to reliably respond to glucose changes in a controlled and reproducible way?

To answer this, our development pathway is structured in clear stages. We begin with concept and design validation, where we define the system architecture and model how glucose-responsive behaviour might emerge from the interaction between polymers, hydrogels, and nanoparticle components. From there, we move into materials optimisation, refining each element of the system to better control stability, responsiveness, and release dynamics.

The next stage involves preclinical validation in controlled laboratory settings, where we assess key parameters such as biocompatibility, structural stability, and insulin release behaviour under simulated physiological conditions. These studies are essential in determining whether the system can perform consistently enough to justify further development.

Finally, we map this work toward translational pathways, including preclinical in vivo studies and regulatory planning across frameworks such as the TGA, FDA, and EMA. This step is less about immediate execution and more about ensuring that every stage of development aligns with what would ultimately be required for clinical translation.

At its core, this is a long-term scientific programme aimed at bridging a fundamental gap in diabetes treatment: moving from externally controlled insulin delivery to a system that is designed to respond to the body itself.